Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 1,826

Document Document Title
WO/2000/054756A2
Compounds and methods for mitigating neurodegeneration, effecting neuroprotection and/or effecting cognition enhancement in a subject are described. Neurological or cognitive conditions are treated by administering to a subject an effect...  
WO/2000/053618A1
The invention relates to 22R-hydroxycholesta-8,14-diene derivatives having general formula (I) wherein R¿1? is OR, OSO¿3?H or =NOR; with R being H, (C¿1-6?)alkyl or (C¿1-6?)acyl; each of R¿2? and R¿3? is independently hydrogen or (...  
WO/2000/051618A1
The invention relates to (androst-5-en-17$g(b)-yl)alkyl sulfoxides and sulfones having general formula (I), wherein R¿1? is (H, OR), (H, OSO¿3?H) or NOR; with R being H, (C¿1-6?)alkyl or (C¿1-6?)acyl; each of R¿2? and R¿3? is indep...  
WO/2000/050441A1
The invention concerns compounds of formula (I) wherein: X, Y, R¿1?, R¿2?, Z, G are as defined in the description, the methods for preparing them and the intermediates in said method, their use as medicine and the pharmaceutical compos...  
WO/2000/047649A1
The invention relates to novel double metal cyanide (DMC) catalyts for producing polyether polyols by polyaddition of alkylene oxides to starter compounds with active hydrogen atoms. The catalyst contains a) double metal cyanide compound...  
WO/2000/047604A1
The present invention relates to pharmaceutically active unsaturated cholestane derivatives, to pharmaceutical compositions comprising them as active substances and to the use of these novel compounds for the preparation of medicaments. ...  
WO/2000/046234A1
The invention concerns steroid derivatives of general formula (I) wherein: OR is selected in the group consisting of the hydroxyl radical (OH), the ether functions wherein R, containing 1 to 8 carbon atoms, is selected among the linear o...  
WO/2000/043408A2
Novel sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and...  
WO/2000/039148A1
The invention relates to new 7$g(a), 17$g(a), 17$g(b)-substituted testosterone derivatives of general formula (I) and their use as pure antiandrogens for the long-term therapy of androgen-dependent diseases, notably for the long-term ant...  
WO/2000/034232A1
Serine carbonates of formula I are precursors for organoleptic compounds, masking agents and antimicrobial agents. Further they are alternative substrates for malodor producing enzymes. The symbols in formula I are defined in claim 1.  
WO/2000/034306A1
The invention is directed to a novel class of 17$g(b)-acyl-17$g(a)-propynyl steroids which exhibit potent antiprogestational activity.  
WO/2000/030688A2
Substituted polycarboxylic ligand molecules and corresponding metal complexes of said ligands, preferably paramagnetic metals complexes for generating responses in the field of magnetic resonance imaging (MRI). The paramagnetic complexes...  
WO/2000/024761A1
The invention relates to substituted phenyl alkenoyl guanidines, the pharmaceutically acceptable salts thereof, and physiolgically functional derivatives. Compounds of formula (I) are disclosed, wherein the radicals have the meanings thu...  
WO/2000/014104A1
The present invention relates to crystalline 11$g(b)-fluoro- 7$g(a)-(14, 14,15,15,15- pentafluoro-6- methyl-10-thia- 6-azapentadecyl) estra-1,3,5(10)- triene-3, 17$g(b)-diol (compound (1)) in the form of a solvate. The crystalline solvat...  
WO/2000/011019A1
The present invention relates to novel compounds comprising a steroid hormone linked to a DNA-interacting molecule that target nucleic acids to the cell nucleus. Further, the invention relates to a method for introducing nucleic acids in...  
WO/2000/011018A1
The present invention relates to novel compounds comprising a steroid hormone linked to a DNA-interacting molecule that target nucleic acids to the cell nucleus. Further, the invention relates to a method for introducing nucleic acids in...  
WO/2000/009137A2
Newly isolated aminosterol compounds and pharmaceutical compositions based on the aminosterol compounds are described. Methods for the treatment of various disorders, for example, a microbial infection, are also described.  
WO/1999/067274A1
The invention concerns compounds of formula (I) wherein, in particular: X = halogen; Y = single bond, O, NH, S, SO or SO¿2?; Z = hydrogen or halogen; n, R¿1?, R¿2?, R¿3? and R¿4? are as defined in the description. The invention also...  
WO/1999/062929A1
The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity.  
WO/1999/062928A1
The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity.  
WO/1999/058549A1
Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.  
WO1999033858A9
Novel compounds useful as inhibitors of estrone sulfatase are provided. The compounds have structural formula (I) wherein r1 is an optional double bond, R<1> and R<2> are selected from the group consisting of hydrogen and lower alkyl, or...  
WO/1999/052932A1
The present invention relates to bile acid or bile salt fatty acid conjugates (hereinafter called 'BAFAC'), to their use in dissolving cholesterol gallstones in bile, preventing their occurrence or recurrence, to their use in reducing or...  
WO1999033859A9
Novel anti-estrogenic compounds are provided which are useful to treat a variety of disorders, particularly estrogen-dependant disorders. Preferred compounds have 1,3,5-estratiene nucleus, and are substituted at the C-17 or C-11 position...  
WO/1999/046279A2
Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17$g(b)-hydroxy...  
WO/1999/046280A1
The invention concerns compounds of formula (I) wherein: R1 represents a C1-C31 hydrocarbon radical, in particular an alkyl radical, linear or branched, saturated or unsaturated; OR2 represents a cholesteryl radical; said compounds being...  
WO/1999/044616A1
A series of novel steroid derivatives are described. The steroid derivatives are antibacterial agents. The steroid derivatives also act to sensitize bacteria to other antibiotics including erythromicin and novobiocin.  
WO/1999/045023A1
The invention relates to S-substituted 11$g(b)-benzaldoxime-estra-4,9-diene-carbonic acid thiolesters of general formula (I) and the pharmaceutically acceptable salts thereof. The invention additionally relates to a method for the produc...  
WO/1999/045024A1
Novel sterol derivatives of formula (I), in which: R?1¿ represents a hydroxyl group or protected hydroxyl group, R?2¿ represents a hydrogen atom and a double bond is present at c, or R?1¿ and R?2¿ together represent an oxo group and ...  
WO/1999/035161A1
A process for producing a compound of formula (I) wherein the dotted lines --- independently represent a single or double bond and R, R¿1?, R¿2? and R¿3? are each hydrogen or an organic radical, comprises treating the corresponding 17...  
WO/1999/033855A1
The invention relates to novel 11$g(b)-halogen-7$g(a)-substituted estratrienes of formula (I), wherein R?11¿ is a fluorine or chlorine atom and the other substituents have the meanings given in the description. The inventive compounds h...  
WO/1999/032127A1
Compositions of angiostatic agents for treating GLC1A glaucoma and methods for their use are disclosed.  
WO/1999/027935A1
A sulphamate compound suitable for use as an inhibitor of oestrone sulphatase (E.C.3.1.6.2) is described. The compound is a polycyclic compound comprising at least two ring components, wherein the polycyclic compound comprises at least o...  
WO/1999/027936A1
A sulphamate compound suitable for use as an inhibitor of oestrone sulphatase (E.C.3.1.6.2) is described. The compound is a polycyclic compound comprising at least two ring components, wherein the polycyclic compound comprises at least o...  
WO/1999/025725A1
The invention concerns compounds of formula (I) in which: X is a halogen atom; D represents the radical of a pentagonal or hexagonal cycle optionally substituted and optionally unsaturated; R¿1?, R¿2?, R¿3?, R¿4?, X and n are as defi...  
WO/1999/020646A1
The invention provides estrogens and antiestrogens of formula (I) having structure (I) wherein R is (II), (III), (IV), or (V); R?1¿ and R?2¿ are each, independently, alkyl of 1-6 carbon atoms, or are alkyl groups which are taken togeth...  
WO/1999/018798A1
The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases (see the dose response curves in the Figure). Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.  
WO/1999/019342A1
The present invention relates to bile acid metal salts of therapeutical interest, as well as to pharmaceutical and veterinary compositions containing said salts.  
WO/1999/015656A2
A new gene in the G-coupled protein receptor family is discribed that is induced by IL-9, thereby providing a therapeutic target in IL-9 mediated development of atopic allergy, asthma-related disorders and certain lymphomas or leukemias....  
WO/1999/015547A1
The invention concerns beverage compositions and acetic acid compositions that contain hydroxy acid, keto acid, dicarboxylic acid or amino acid esters of a phytosterol and/or a phytostanol, or their salts, the amine salts of amino acid e...  
WO/1999/015546A1
The invention concerns dietary fat compositions that contain the hydroxy acid or dicarboxylic acid or amino acid esters of a phytosterol and/or phytostanol, or the mixed esters formed with the alcohols, polyols or polyol (C¿2?...C¿22?)...  
WO/1999/005094A1
This invention features permeability enhancer molecules, and methods, to increase membrane permeability of negatively charged polymers thereby facilitating cellular uptake of such polymers.  
WO/1999/003503A1
Methods for treating ocular neovascularization using photodynamic therapy in combination with an angiostatic steroid are disclosed.  
WO/1999/003876A1
Sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of a patient are also disclosed.  
WO/1998/056812A2
Crystal comprising at least part of the ER$g(a) ligand binding domain, optionally bound to a ligand, ligands that bind to ER receptors, and methods of designing them, and a homology model of the ER$g(b) receptor.  
WO/1998/055499A1
The invention relates to 11$g(b)-aryl-substituted 14,17-ethano-oestratriens of general formula (I), in which R?1� is a hydrogen atom, a C�1?-C�12?-alkanoyl-, a benzoyl-, a straight-chain or branched C�1?-C�12?-alkyl-, a C�3?-...  
WO/1998/055496A1
New non-estrogenic estradiol derivatives with an antioxidant effect are disclosed. These estradiol derivatives, which have no estrogenic effect but a high antioxidant effect, are potentially useful as non-estrogenic antioxidants, in part...  
WO/1998/052965A1
The invention relates to 20-aralkyl-5$g(a)-pregnane derivative having general formula (I), or a pharmaceutically acceptable salt thereof, wherein R�1? is (H,OR), (H,OSO�3?H) or NOR; R is H, (C�1-6?)alkyl or (C�1-6?)acyl; each of ...  
WO/1998/050418A1
Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more ca...  
WO/1998/050417A1
Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more ca...  

Matches 401 - 450 out of 1,826